Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NovoTTF-200A Alone and Combined With Temozolomide in Low-Grade Gliomas
NCT02507232Phase 1Terminated
- Sponsor
- Santosh Kesari
- Start
- Apr 2017
- Primary completion
- Jul 2020
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial (2 arms), sponsored by Santosh Kesari. Primary endpoint: Toxicity associated with treatment at 24 months. Started Apr 2017; status: terminated.
Beyond the preview
Go deeper on NCT02507232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02507232.